Politico reports that the Trump administration has allocated another $10 billion for rural health, rewarding some states and penalising others based on their 2025 record on MAHA and related priorities. The article notes that these changes come as larger Medicaid cuts are under consideration.
This development matters for healthcare and insurance leaders, as it signals shifting federal support and the potential for uneven impacts across states. Changes in funding could affect access to care, reimbursement rates, and the design of state-level health programmes. Leaders should monitor federal policy signals and prepare for possible changes in Medicaid funding.
Politico reports that Republicans have joined Democrats in blaming large pharmacy groups, including CVS, for high drug prices. The article points to rising bipartisan political pressure on pharmacy benefit managers, which play a major role in the US drug supply chain.
This matters for senior executives in healthcare and pharma, as it signals a shift in the political environment. Bipartisan scrutiny may lead to tougher regulation or changes in how pharmacy benefit managers operate. Leaders should monitor for possible policy changes affecting pricing, contracts and market access.
The White House decided to stop moving forward with an executive order that would have shifted control over NIH research grants to political appointees, maintaining the traditional, non-partisan management of scientific funding.
The Supreme Court's refusal to review cases brought by pharmaceutical companies marks a pivotal moment, signaling strong judicial support for continued Medicare price negotiations. This decision effectively blocks the pharmaceutical industry's attempts to derail efforts aimed at lowering drug costs for Medicare recipients, underscoring a shift towards increased government influence in healthcare pricing.
A recent data exposure related to a CMS provider directory, designed to enhance the accuracy of insurer networks, has inadvertently revealed doctors' Social Security numbers.
Due to the ongoing budget deadlock, some hospitals are compelled to stop offering the Medicare hospital-at-home program, which has successfully enabled the treatment of severely ill patients in their own homes.